Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas R. Kosten, MD, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00142948
First received: September 1, 2005
Last updated: October 22, 2012
Last verified: October 2012

September 1, 2005
October 22, 2012
February 2006
May 2011   (final data collection date for primary outcome measure)
Heroin relapse [ Time Frame: duration of study ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00142948 on ClinicalTrials.gov Archive Site
  • HIV risk factors [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Psychiatric symptoms (measured at Month 6, and the 3- and 6-month follow-up evaluations) [ Time Frame: months 6 and the 3- and 6-month follow-up evaluations ] [ Designated as safety issue: No ]
  • Adherence to medication [ Time Frame: duration of study ] [ Designated as safety issue: No ]
  • Heroin withdrawal symptoms [ Time Frame: Month 6, and 3- and 6-month followup ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts
Heroin Addiction Treatment: Naltrexone and Adrenergic Agents

Naltrexone is a medication that is currently used to treat drug and alcohol addiction. Guanfacine is a medication that is currently used to manage the withdrawal symptoms in individuals undergoing opioid detoxification. A combination of these two medications may be beneficial in reducing heroin use in individuals addicted to heroin. This study will evaluate the effectiveness of naltrexone and guanfacine, alone and in combination, at reducing heroin use in heroin addicts.

Heroin addiction is a serious health problem with no available medical treatment for preventing relapse. Naltrexone is a medication that is currently used to treat substance addiction. It acts by blocking the "high" feeling produced by drugs and alcohol. Guanfacine, an antihypertensive medication, is currently used to manage the withdrawal symptoms in individuals undergoing opioid detoxification. While each of these medications is useful in the treatment of heroin addiction, a combination of the two drugs may be more effective than either medication alone. The purpose of this study is to compare the effectiveness of naltrexone, guanfacine, and a combination of naltrexone and guanfacine at reducing drug relapse in heroin addicts.

This study will enroll individuals addicted to heroin who have completed a prior detoxification program at one of two addiction treatment hospitals in St. Petersburg, Russian Federation. Upon completing the detoxification program of 7-14 days, participants will have a period of inpatient rehabilitation. During this 3- to 4-week inpatient stabilization period, patients will be screened for study participation. Once stabilized, participants will begin the 6-month treatment phase of the study. During this phase, they will be randomly assigned to receive one of the following drug combinations on a daily basis: 50 mg of naltrexone and guanfacine placebo; 1.0 mg of guanfacine and naltrexone placebo; 50 mg of naltrexone and 1.0 mg of guanfacine; or naltrexone placebo and guanfacine placebo. All participants will have a designated family member who will be responsible for supervising medication compliance. Study visits will occur twice monthly. Participants will receive clinical management and medication compliance counseling at each visit; family members will also take part in the counseling sessions. Outcome measurements will include drug relapse, medication adherence, withdrawal symptoms, HIV risk factors, and psychiatric symptoms. Follow-up evaluations will occur 3 and 6 months following the end of treatment.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Heroin Dependence
  • Drug: Naltrexone
    naltrexone
  • Drug: Placebo
    placebo
  • Experimental: Naltrexone
    Naltrexone Oral 50 mgs daily
    Intervention: Drug: Naltrexone
  • Placebo Comparator: Placebo
    1 to 1 comparison of Naltrexone to placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
301
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Current primary diagnosis of heroin dependence, for at least 1 year prior to study entry
  • High school graduate or higher education level
  • Abstinence from drugs and alcohol for at least 1 week prior to study entry
  • Negative urine and breathalyzer tests for alcohol and drugs
  • No evidence of opioid dependence following narcan challenge
  • At least one relative willing to participate in treatment, monitor administration of medications, assist in follow-up, and provide outcome data
  • Stable address within St. Petersburg or nearest districts of Leningrad Region
  • Able to provide a home telephone number where the participant may be reached
  • If female, willing to use effective contraception throughout the study

Exclusion Criteria:

  • Low blood pressure, as determined by sitting blood pressure less than 90/50 mm Hg
  • Clinically significant cognitive impairment, schizophrenia, paranoid disorder, bipolar disorder, or seizure disorder
  • Advanced brain, heart, kidney, or liver disease
  • Active tuberculosis
  • Current febrile illness
  • AIDS-defining illness
  • Significant laboratory abnormality, including severe anemia, unstable diabetes, or liver function tests greater than three times above normal
  • Pending legal issues that may entail a jail stay during the study
  • Currently participating in another treatment study
  • Currently participating in another substance abuse program
  • Current use of a psychotropic medication
  • Pregnant
  • Pulse rate less than 50 bpm
Both
18 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT00142948
NIDA-18863, R01DA018863, DPMC
Yes
Thomas R. Kosten, MD, Baylor College of Medicine
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)
Principal Investigator: Thomas R. Kosten, MD Baylor College of Medicine
Baylor College of Medicine
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP